Supplementary Table 6. The AUROC between SAFE score and specific HBV-related HCC risk scores

AUROC	N	1 year	3 years	5 years
CHB without antiviral therapy				
REACH-B	1,008	0.69	0.72	0.75
SAFE	1,008	0.82	0.82	0.84
P-value		0.25	0.23	0.09
CU-HCC	897	0.94	0.86	0.82
SAFE	897	0.84	0.82	0.83
P-value		0.12	0.20	0.76
CHB receiving antiviral therapy				
PAGE-B	986	0.87	0.79	0.80
SAFE	986	0.81	0.76	0.80
P-value		0.31	0.52	0.98

AUROC, areas under receiver operating characteristic curves; SAFE, Steatosis-Associated Fibrosis Estimator; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B; CU-HCC, Chinese University-HCC; PAGE-B, platelet age gender–HBV.

 https://doi.org/10.3350/cmh.2024.0822